CBL0137 is being investigated primarily for its potential in cancer therapy. It functions by targeting and inhibiting the FACT complex, a protein involved in DNA transcription and repair, which is often overactive in cancer cells. By disrupting this complex, CBL0137 can induce cancer cell death while sparing normal cells, making it a promising candidate for treating various cancers, including solid tumors and hematologic malignancies. Clinical trials are ongoing to evaluate its efficacy and safety in humans, with a focus on its potential as a single-agent therapy or in combination with other treatments. Its unique mechanism of action offers hope for overcoming drug resistance in certain cancers.